Companies: 10,795·Total market cap: $144.5T
Akari Therapeutics, Plc

Akari Therapeutics, Plc

AKTXNASDAQHealthcare● Active
$15.45
+$0.38(+2.49%)
Market Cap$17678146
P/E Ratio—
52W High$52
52W Low$3.015
Overview
Foreign Private Issuer · Files 20-F / 6-K

Akari Therapeutics, Plc (AKTX) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001541157 · AKTX · NASDAQ · as of Jun 10, 2026

Filing snapshot

713
Total Filings
SCHEDULE 13G
Latest Form
2026-06-08
Most Recent
2014
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001541157 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-30
Fiscal Year End
Mar 30, 2026
Accession No.
0001493152-26-013664
Primary Document
form10-k.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001541157 · Accession 0001493152-26-013664

Latest Key Filings

6-KQuarterly Report
FORM 6-K
2023-12-01
View 6-K on SEC
8-KCurrent Report
8-K
2026-05-22Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-06-08
View
DEF 14AProxy Statement
DEF 14A
2026-06-04
View
DD
D
2026-06-03
View
PRE 14APRE 14A
PRE 14A
2026-05-22
View
8-KCurrent Report
8-K
2026-05-22
View
RWRW
RW
2026-05-21
View
10-QQuarterly Report
10-Q
2026-05-19
View
NT 10-QNT 10-Q
NT 10-Q
2026-05-18
View
S-1IPO Registration Statement
S-1
2026-05-08
View
EFFECTEFFECT
EFFECT
2026-04-15
View
POS AMPOS AM
POS AM
2026-04-10
View
DRSDRS
DRS
2026-04-02
View
F-6/AF-6/A
F-6/A
2026-03-31
View
10-KAnnual Report
10-K
2026-03-30
View
8-KCurrent Report
8-K
2026-03-17
View
Showing 1–15 of 628 filingsForm 4 / 144 hidden· 713 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001541157  |  Exchange: NASDAQ · Healthcare

Akari Therapeutics, Plc (NASDAQ: AKTX) has submitted 713 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2014. As a Healthcare sector company with CIK 0001541157, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Akari Therapeutics, Plc's most comprehensive regulatory disclosure. The most recent Akari Therapeutics, Plc 10-K was filed on 2026-03-30 for fiscal year ending 2026. Historical AKTX 10-K annual reports are available from 2012 through 2026.

Investors researching Akari Therapeutics, Plc SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-10
Related Companies SEC Filings — Healthcare
REVB SEC Filings →CDT SEC Filings →DRMA SEC Filings →XAGE SEC Filings →PPBT SEC Filings →MSPR SEC Filings →VINC SEC Filings →PBM SEC Filings →
→ AKTX Financials→ AKTX Earnings→ AKTX Insider Trades

Frequently Asked Questions

AKTX SEC Filings · 8 questions

Akari Therapeutics, Plc (AKTX) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 713 filings and access original documents at no cost. Akari Therapeutics, Plc's CIK is 0001541157.

AKTX SEC filingsAkari Therapeutics, Plc SEC documentsfind AKTX 10-K